Klein R G, Eek B C, DeLong W B, Mooney V
Sansum Medical Clinic, Department of Orthopaedic Medicine, Santa Barbara, CA 93102-1239.
J Spinal Disord. 1993 Feb;6(1):23-33.
This randomized clinical trial evaluated the efficacy of injections of a dextrose-glycerine-phenol connective tissue proliferant into the posterior ligaments, fascia, and joint capsules to treat chronic low back pain. Seventy-nine patients with chronic low back pain that had failed to respond to previous conservative care were randomly assigned to receive a double-blind series of six injections at weekly intervals of either Xylocaine/saline solution or Xylocaine/proliferant into the posterior sacroiliac and interspinous ligaments, fascia, and joint capsules of the low back from L4 to the sacrum. Patients were observed with a visual analog, disability, and pain grid scores, and with objective computerized triaxial tests of lumbar function for 6 months following conclusion of injections. Pretreatment imaging tests with either magnetic resonance imaging (MRI) or computed tomography (CT) scans were performed in all patients. Thirty of the 39 patients randomly assigned to the proliferant group achieved a 50% or greater diminution in pain or disability scores at 6 months compared to 21 of 40 in the group receiving lidocaine (p = 0.042). Subjective parameters measured at 6 months posttreatment improved (p < 0.001) overall in both the treatment and control group compared to baseline. Improvements in visual analog (p = 0.056), disability (p = 0.068), and pain grid scores (p = 0.025) were greater in the proliferant group. Objective testing of range of motion, isometric strength, and velocity of movement showed significant improvements in both groups following treatment but did not favor either group. The MRI and CT scans showed significant abnormalities in both groups, but these did not correlate with subjective complaints and were not predictive of response to treatment.
这项随机临床试验评估了向后方韧带、筋膜和关节囊注射葡萄糖 - 甘油 - 苯酚结缔组织增殖剂治疗慢性腰痛的疗效。79例对先前保守治疗无反应的慢性腰痛患者被随机分配,接受双盲系列的六次注射,每周一次,分别向L4至骶骨的腰骶部后方骶髂韧带、棘间韧带、筋膜和关节囊注射利多卡因/生理盐水溶液或利多卡因/增殖剂。在注射结束后的6个月内,通过视觉模拟评分、残疾评分和疼痛网格评分以及腰椎功能的客观计算机化三轴测试对患者进行观察。所有患者均进行了磁共振成像(MRI)或计算机断层扫描(CT)扫描的治疗前影像检查。随机分配到增殖剂组的39例患者中有30例在6个月时疼痛或残疾评分降低了50%或更多,而接受利多卡因治疗的40例患者中有21例(p = 0.042)。与基线相比,治疗组和对照组在治疗后6个月测量的主观参数总体上均有改善(p < 0.001)。增殖剂组在视觉模拟评分(p = 0.056)、残疾评分(p = 0.068)和疼痛网格评分(p = 0.025)方面的改善更大。运动范围、等长力量和运动速度的客观测试显示,两组治疗后均有显著改善,但对两组均无明显优势。MRI和CT扫描显示两组均有明显异常,但这些异常与主观症状无关,也不能预测治疗反应。